The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: A new class of Aurora-A kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 22, 2006, Pages 5778-5783

  Moriarty, Kevin J ^a   Koblish, Holly K ^a   Garrabrant, Thomas ^a   Maisuria, Jahanvi ^a   Khalil, Ehab ^a   Ali, Farah ^a   Petrounia, Ioanna P ^a   Crysler, Carl S ^a   Maroney, Anna C ^a   Johnson, Dana L ^a   Galemmo Jr , Robert A ^a  

^a PRDUS LLC   (United States)

Author keywords

2 Amino pyrrolo 2,3 d pyrimidine; Anti proliferative; Aurora A; Polyploidy

Indexed keywords

AURORA A KINASE; ENZYME INHIBITOR; NANOPARTICLE; PYRROLOPYRIMIDINE DERIVATIVE;

ARTICLE; BIOCHEMISTRY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PLOIDY; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; TUMOR CELL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; POLYPLOIDY; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33749238184     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.08.080     Document Type: Article

References (13)

1. Bischoff J.R., and Plowman G.D. Trends Cell Biol. 9 (1999) 454
2. Zhou H., Kuang J., Zhong L., Kuo W.L., Gray J.W., Sahin A., Brinkley B.R., and Sen S. Nat. Genet. 20 (1998) 189
3. Katayama H., Brinkley W.R., and Sen S. Cancer Metastasis Rev. 22 (2003) 451
4. Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., Fujii S., Arlinghaus R.B., Czerniak B.A., and Sen S. Nat. Genet. 36 (2004) 55
5. Ota T., Suto S., Katayama H., Han Z.B., Suzuki F., Maeda M., Tanino M., Terada Y., and Tatsuka M. Cancer Res. 62 (2002) 5168
6. Tatsuka M., Katayama H., Ota T., Tanaka T., Odashima S., Suzuki F., and Terada Y. Cancer Res. 58 (1998) 4811
7. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., Graham J.A., Demur C., Hercend T., Diu- Hercend A., Su M., Golec J.M.C., and Miller K.M. Nat. Med. 10 (2004) 262
8. Cheung M., Harris P.A., and Lackey K.E. Tetrahedron Lett. 42 (2001) 999
9. Lam P.Y.S., Clark C.G., Saubern S., Adams J., Averill K.M., Chan D.M.T., and Combs A. Synlett (2000) 674
10. Strieter E.R., Blackmond D.G., and Buchwald S.L. J. Am. Chem. Soc. 127 (2005) 4120
11. Lebedev A.Y., Khartulyari A.S., and Voskoboynikov A.Z. J. Org. Chem. 70 (2005) 596
12. During preparation of this manuscript a series of pyrrolopyrimidine inhibitors of FAK kinase was disclosed. None of our inhibitors exhibited any activity against the FAK kinase. Choi H.-S., Wang Z., Richmond W., He X., Yang K., Jiang T., Sim T., Karanewsky D., Gu X.-j., Zhou V., Liu Y., Ohmori O., Caldwell J., Gray N., and He Y. Bioorg. Med. Chem. Lett. 16 (2006) 2173
13. Ditchfield C., Johnson V.L., Tight A., Ellston R., Haworth C., Johnson T., Mortlock A., Keen N., and Taylor S.S. J. Cell Biol. 161 (2003) 267